1. Immunology/Inflammation
    Apoptosis
  2. PD-1/PD-L1
    Apoptosis
  3. BMS-202

BMS-202 

Cat. No.: HY-19745 Purity: 98.45%
Handling Instructions

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.

For research use only. We do not sell to patients.

BMS-202 Chemical Structure

BMS-202 Chemical Structure

CAS No. : 1675203-84-5

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 132 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 132 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 120 In-stock
Estimated Time of Arrival: December 31
10 mg USD 192 In-stock
Estimated Time of Arrival: December 31
25 mg USD 396 In-stock
Estimated Time of Arrival: December 31
50 mg USD 696 In-stock
Estimated Time of Arrival: December 31
100 mg USD 1140 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of BMS-202:

Top Publications Citing Use of Products

    BMS-202 purchased from MCE. Usage Cited in: Drug Dev Res. 2021 Jul 26.

    Cultured Lβt2 cells are treated with 25 μM BMS-202 and collected at 24 h. the p-p38 MAPK, p38 MAPK, p-JNK, JNK, p-ERK, ERK, and α-tubulin protein levels are detected by Western Blotting.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity[1][2].

    IC50 & Target

    IC50: 18 nM (PD-1/PD-L1)[1]
    KD: 8 μM (PD-1/PD-L1)[1]

    In Vitro

    BMS-202 (0-100 μM; 4 days; SCC-3 or Jurkat cells) treatment inhibits the proliferation of strongly PD-L1-positive SCC-3 cells (IC50 of 15 μM) and anti-CD3 antibody-activated Jurkat cells (IC50 10 μM) in vitro[2].
    BMS-202 selectively induces thermal stabilization of PD-L1. BMS-202 induces dimerization of PD-L1 in solution.BMS-202 is located at the center of the homodimer filling a deep hydrophobic pocket contributing multiple additional interactions between the monomers. BMS-202 interacts with both PD-L1 molecules using hydrophobic surfaces physiologically involved in the PD-1/PD-L1 interaction[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[2]

    Cell Line: SCC-3 or Jurkat cells
    Concentration: 0-100 μM
    Incubation Time: 4 days
    Result: Inhibited the proliferation of strongly PD-L1-positive SCC-3 cells (IC50 of 15 μM) and anti-CD3 antibody-activated Jurkat cells (IC50 10 μM) in vitro.
    In Vivo

    BMS-202 (20 mg/kg; intraperitoneal injection; daily; for 9 days; NOG-dKO mice) treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NOG-dKO mice (8-week-old) injected with SCC-3 cells[2]
    Dosage: 20 mg/kg
    Administration: Intraperitoneal injection; daily; for 9 days
    Result: Showed 41% growth inhibitory activity against humanized mouse-transplanted human lymphoma SCC-3 cells.
    Molecular Weight

    419.52

    Formula

    C₂₅H₂₉N₃O₃

    CAS No.
    SMILES

    CC(NCCNCC1=CC=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)N=C1OC)=O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (238.37 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3837 mL 11.9184 mL 23.8368 mL
    5 mM 0.4767 mL 2.3837 mL 4.7674 mL
    10 mM 0.2384 mL 1.1918 mL 2.3837 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (5.96 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (5.96 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (5.96 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 98.45%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    BMS-202BMS202BMS 202PD-1/PD-L1ApoptosisPD-1/Programmed death-ligand 1Thermal stabilizationnonpeptidicdimerichydrophobicantitumoranti-proliferationimmune-responseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    BMS-202
    Cat. No.:
    HY-19745
    Quantity:
    MCE Japan Authorized Agent: